

Appendix 6 - 510(k) Summary

AUG 22 2006

Submitter:	Edwards Lifesciences LLC One Edwards Way Irvine, CA 92614-5686
Contact Person:	Jason Smith, Project Manager, Regulatory Affairs
Date Prepared:	July 25, 2006
Trade name:	Vigileo APCO/Oximetry Monitor
Classification Name:	Cardiac Output/Oximeter Computer Single-Function, Preprogrammed Diagnostic Computer (21 CFR 870.1435)
Predicate Device:	Vigileo APCO/Oximetry Monitor
Device Description:	The Vigileo APCO/Oximetry Monitor is a microprocessor-based instrument which, when connected to a FloTrac sensor, continuously measures arterial pressure cardiac output (APCO). When connected to an Edwards oximetry catheter, the monitor measures oxygen saturation (oximetry) in adults or pediatrics. The monitor also calculates other derived parameters including cardiac index, stroke volume, stroke volume index, stroke volume variation, systemic vascular resistance, systemic vascular resistance, delivered oxygen, delivered oxygen index, and pulse oximetry saturation.
Intended Use:	The Vigileo APCO/Oximetry Monitor is intended to measure arterial pressure cardiac output and oximetry. The monitor also calculates derived hemodynamic and oxygenation parameters.
Comparative Analysis:	The Vigileo APCO/Oximetry Monitor has been demonstrated to be as safe and effective as the predicate device for its intended use.
Functional/Safety Testing:	The Vigileo APCO/Oximetry Monitor has successfully undergone functional testing demonstrating equivalence to the predicate device.
Conclusion:	The Vigileo APCO/Oximetry Monitor is substantially equivalent to the predicate device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AUG 22 2006

Edwards Lifesciences, LLC.
c/o Mr. Jason Smith
Project Manager, Regulatory Affairs
One Edwards Way
Irvine, CA 92614

Re: K062134

Trade Name: Vigilew APCO/Oximetry Monitor
Regulation Number: 21 CFR 870.1435
Regulation Name: Single-Function, Preprogrammed Diagnostic Computer
Regulatory Class: Class II (two)
Product Code: DXG
Dated: July 25, 2006
Received: July 26, 2006

Dear Mr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act.

Page 2 – Mr. Jason Smith

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

July, 2006

Appendix 2 - Indications for Use Statement

510(k) Number (if known): K062134

Device Name: Vigileo APCO/Oximetry Monitor

Indications for Use:

The Vigileo APCO/Oximetry Monitor is indicated for continuously measuring hemodynamic parameters such as cardiac output and oximetry to assess oxygen delivery and consumption. When connected to an Edwards oximetry catheter, the monitor measures oximetry in adults and pediatrics.

Prescription Use X _____ AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

B. Zimmerman
(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K062134

Page 1 of 1